JAC Advance Access originally published online on December 12, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 147-151
© 2003 The British Society for Antimicrobial Chemotherapy
Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance
1 Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera Majadahonda a Pozuelo, Km. 2, 28220 Majadahonda, Madrid; 2 Servicio de Microbiología, Hospital Ramón y Cajal, Madrid, Spain
Received 21 May 2002; returned 8 August 2002; revised 19 September 2002; accepted 19 October 2002
The activities of nalidixic acid, ciprofloxacin, norfloxacin, ofloxacin, pefloxacin, flerofloxacin, sparfloxacin, grepafloxacin, gatifloxacin, moxifloxacin, trovafloxacin, levofloxacin and clinafloxacin against a panel of Haemophilus influenzae strains were assessed by three susceptibility testing methods: Etest, agar dilution and the reference broth microdilution method using Haemophilus test medium (HTM) in all cases. The panel included 62 clinical and two reference H. influenzae strains; 32 had decreased susceptibility to ciprofloxacin (MIC 
0.12 mg/L) and 30 were susceptible to this antibiotic (MIC 
0.06 mg/L). Both Etest and HTM agar dilution results (r = 0.96; 86.61% and 82.1% of MICs within + one log2, respectively) correlated well with the reference microdilution method. The MIC90 of ciprofloxacin was 4.0 mg/L (range 0.007–32.0 mg/L). Trovafloxacin activity was similar to that of ciprofloxacin but sparfloxacin, grepafloxacin, ofloxacin, pefloxacin and flerofloxacin activities were higher (with MIC values one log2 dilution lower than ciprofloxacin). The least active were norfloxacin (MIC90 16 mg/L) and nalidixic acid (MIC90 128 mg/L). Levofloxacin and moxifloxacin were more active than ciprofloxacin (MIC90 2 mg/L); clinafloxacin and gatifloxacin were the most active with an MIC90 of 0.25 mg/L. Cross-susceptibility among all quinolones was observed (r > 0.9). Resistance to ciprofloxacin was associated with a similar magnitude of activity loss to other new and old quinolones. Ciprofloxacin MIC determination should be sufficient to detect the decreased susceptibility to the whole group of quinolones.
Keywords: Haemophilus influenzae, antibiotic resistance, quinolones, susceptibility testing methods
* Corresponding author. Tel: +34-91-509-7901, ext. 3650, 3643; Fax: +34-91-509-7966; E-mail: jcampos{at}isciii.es
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Nakamura, K. Yanagihara, Y. Morinaga, K. Izumikawa, M. Seki, H. Kakeya, Y. Yamamoto, S. Kamihira, and S. Kohno Melting Curve Analysis for Rapid Detection of Topoisomerase Gene Mutations in Haemophilus influenzae J. Clin. Microbiol., March 1, 2009; 47(3): 781 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Perez-Vazquez, F. Roman, S. Garcia-Cobos, and J. Campos Fluoroquinolone Resistance in Haemophilus influenzae Is Associated with Hypermutability Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1566 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, N. Mariano, J. J. Rahal, C. M. Urban, and K. Drlica Quinolone-Resistant Haemophilus influenzae: Determination of Mutant Selection Window for Ciprofloxacin, Garenoxacin, Levofloxacin, and Moxifloxacin Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4460 - 4462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Roman, R. Canton, M. Perez-Vazquez, F. Baquero, and J. Campos Dynamics of Long-Term Colonization of Respiratory Tract by Haemophilus influenzae in Cystic Fibrosis Patients Shows a Marked Increase in Hypermutable Strains J. Clin. Microbiol., April 1, 2004; 42(4): 1450 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perez-Vazquez, F. Roman, B. Aracil, R. Canton, and J. Campos Laboratory Detection of Haemophilus influenzae with Decreased Susceptibility to Nalidixic Acid, Ciprofloxacin, Levofloxacin, and Moxifloxacin Due to gyrA and parC Mutations J. Clin. Microbiol., March 1, 2004; 42(3): 1185 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perez-Vazquez, F. Roman, B. Aracil, R. Canton, and J. Campos In Vitro Activities of Garenoxacin (BMS-284756) against Haemophilus influenzae Isolates with Different Fluoroquinolone Susceptibilities Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3539 - 3541. [Abstract] [Full Text] [PDF]
|
|